ES2058351T3 - Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario. - Google Patents

Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario.

Info

Publication number
ES2058351T3
ES2058351T3 ES89101428T ES89101428T ES2058351T3 ES 2058351 T3 ES2058351 T3 ES 2058351T3 ES 89101428 T ES89101428 T ES 89101428T ES 89101428 T ES89101428 T ES 89101428T ES 2058351 T3 ES2058351 T3 ES 2058351T3
Authority
ES
Spain
Prior art keywords
producing
human
procedure
release formulation
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101428T
Other languages
English (en)
Inventor
Keiji Sumitomo Pharmac Fujioka
Shigeji Sumitomo Pharmace Sato
Nobuhiko Sumitomo Pharm Tamura
Yoshihiro Sumitomo Phar Takada
Yoshio C O Sumitomo Pha Sasaki
Miho C O Sumitomo Pharma Maeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Pharmaceuticals Co Ltd filed Critical Koken Co Ltd
Application granted granted Critical
Publication of ES2058351T3 publication Critical patent/ES2058351T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACION DE LIBERACION CONTROLADA QUE CONTIENE UN COMPUESTO ORGANICO ACIDO O UN ANHIDRIDO DE ACIDO O UN ESTER CAPAZ DE GENERAR UNO DE LOS COMPUESTOS ORGANICOSA ACIDOS POR HIDROLISIS, JUNTO CON UN INGREDIENTE ACTIVO Y COLAGENO COMO VEHICULO, SIENDO DICHA FORMULACION CAPAZ DE EXHIBIR UN PERFIL DE LIBERACION PREDETERMINADO DEL INGREDIENTE ACTIVO. SE INCLUYE UN PROCESO PARA PRODUCIR DICHA FORMULACION.
ES89101428T 1988-01-29 1989-01-27 Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario. Expired - Lifetime ES2058351T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2045988 1988-01-29

Publications (1)

Publication Number Publication Date
ES2058351T3 true ES2058351T3 (es) 1994-11-01

Family

ID=12027662

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101428T Expired - Lifetime ES2058351T3 (es) 1988-01-29 1989-01-27 Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario.

Country Status (6)

Country Link
US (1) US5236704A (es)
EP (1) EP0326151B1 (es)
AT (1) ATE90570T1 (es)
CA (1) CA1338839C (es)
DE (1) DE68907066T2 (es)
ES (1) ES2058351T3 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
GR1002610B (el) * 1991-01-02 1997-02-20 Johnson & Johnson Consumer Products Inc. Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
CA2107473A1 (en) * 1991-04-08 1992-10-09 Keiji Fujioka Porous solid formulations containing proteinaceous physiologically active substances
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
WO1995002411A1 (en) * 1993-07-16 1995-01-26 Mallinckrodt Veterinary Limited Stabilised polypeptide growth factor formulation at low ph
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
ATE310839T1 (de) 1994-04-29 2005-12-15 Scimed Life Systems Inc Stent mit kollagen
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
DE19739031A1 (de) * 1997-09-05 1999-03-11 Suwelack Nachf Dr Otto Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung
ES2288018T3 (es) * 1998-04-03 2007-12-16 Novartis Vaccines And Diagnostics, Inc. Formulaciones inyectables de igf que contienen succinato como tampon.
KR100600464B1 (ko) * 1998-05-22 2006-07-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 안정한 유전자 제제
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
AU2003244459A1 (en) * 2002-02-04 2003-09-02 Koken Co., Ltd. Preparations for treating bone fracture or bone loss or elevating bone density
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2540838C (en) 2003-10-03 2014-12-16 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US7718616B2 (en) * 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2661240T3 (es) 2009-04-23 2018-03-28 Jbs United Animal Health Ii Llc Método y composición para sincronizar el momento de inseminación
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
WO2014085674A1 (en) 2012-11-28 2014-06-05 Jbs United Animal Health Ii Llc Method for synchronizing time of insemination in gilts
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2926691A1 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294241A (en) * 1977-06-09 1981-10-13 Teruo Miyata Collagen skin dressing
US4164559A (en) * 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
EP0037943B1 (en) * 1980-03-31 1985-08-14 Teijin Limited Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
DE3250023T (es) * 1981-01-14 1990-03-29
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
JPS597684A (ja) * 1982-07-05 1984-01-14 株式会社日立製作所 エスカレ−タ−
JPS5919925A (ja) * 1982-07-27 1984-02-01 Stanley Electric Co Ltd ２層式液晶セルの製造方法
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3486029T2 (de) * 1983-10-14 1993-05-13 Sumitomo Pharma Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung.
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3409372A1 (de) * 1984-03-14 1985-09-19 Dr. Ruhland Nachf. GmbH, 8425 Neustadt Material zum vitalisieren von implantatoberflaechen
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5057317A (en) * 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法

Also Published As

Publication number Publication date
EP0326151A2 (en) 1989-08-02
DE68907066D1 (de) 1993-07-22
DE68907066T2 (de) 1993-12-16
ATE90570T1 (de) 1993-07-15
EP0326151A3 (en) 1991-03-13
US5236704A (en) 1993-08-17
CA1338839C (en) 1997-01-14
EP0326151B1 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
ATE90570T1 (de) Verbesserte formulierungen mit kontrollierter abgabe.
ES2153355T3 (es) Procedimiento para la preparacion de microesferas que contienen compuestos biologicamente activos.
MX9203653A (es) Composiciones amfotericas y formas polimericas de los alfa-hidroxiacidos.
BR9205711A (pt) Compostos de flúor alquenila e seu uso como repelente para insetos
ES2156156T3 (es) Compuesto terapeutico - conjugados de acidos grasos.
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
GT199600098A (es) Formulaciones de quinolona inyectables.
MX9202982A (es) Derivados de los acidos quinolon - y naftiridon - carboxilicos, procedimiento para su obtencion y medicamentos que los contienen.
ES2083392T3 (es) Sustancia pf 1022, procedimiento para su preparacion y composicion antihelmintica que contiene esta sustancia.
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
ES2130472T3 (es) Guanididas de acidos alquenilcarboxilicos sustituidas con fenilo, portadoras de grupos perfluoroalquilo, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que las contiene.
ES2171722T3 (es) Nuevos derivados de la 5-o-desosaminil-6-o-metil-eritronolida a, su procedimiento de preparacion y su aplicacion a la preparacion de productos biologicamente activos.
ES2013796A6 (es) Agente cosmetico a base de derivados de pirimidina y retinoides, y procedimiento para prepararlo.
ES2139965T3 (es) Benzoilguanidinas sustituidas con grupos de caracter basico, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
MX9205132A (es) Derivados de acidos carboxilicos heterociclicos, procedimiento para su obtencion y medicamentos que los contienen.
MX9300395A (es) Derivados de oxazolina y proceso para su produccion
PT98121A (pt) Processo para a preparacao de novos 3,3'-ditio-bis (acidos propionicos) e seus esteres e de composicoes farmaceuticas que os contem
ES2064983T3 (es) Dispositivo para el tratamiento termico y/o humectacion de carretes, canillas y conos.
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2018796B3 (es) Procedimiento para obtener un agente conservador de la madera
ES2115916T3 (es) Procedimiento para la preparacion de compuestos de triazolona.
MX9301608A (es) Acidos 7-oxo-7h-pirido(1,2,3,de)(1,4)benzoxacin-6-carboxilico y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
FI903905A7 (fi) Menetelmä uusien estereiden, ja niiden suolojen, valmistamiseksi orgaanisista hapoista 19-nor-steroidien alkoholijohdannaisten kanssa

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 326151

Country of ref document: ES